Pillar 1
Intelligence
Know what's happening in FDA enforcement before it happens to you. Warning letter analysis, 483 trends, and enforcement pattern recognition — written for quality teams, not lawyers.
What happens here
FDA Warning Letter Analysis
Every significant warning letter broken down — what FDA cited, why it matters, and what it means for your quality system.
483 Trend Reports
Pattern analysis across 483 observations. See which findings are escalating and where your risk exposure sits.
Regulatory Guidance Updates
ICH, EMA, USP, and FDA guidance changes — summarized with plain-language impact assessment for your operations.
Weekly Intelligence Digests
Curated weekly roundup of the enforcement actions and guidance changes that matter most to small pharma quality teams.
Articles stay in the quality intelligence loop.
The article rail is back in the redesigned homepage: current regulatory analysis, quality science, and guidance watch pieces stay one click from the vault and readiness paths.
June 2026
Media-Fill Failure Is Not the Root Cause. It Is the Alarm Bell.
FDA’s May 18, 2026 warning letter to Sato Pharmaceutical describes six consecutive media-fill failures as a quality-system credibility collapse. The inspection-readiness lessons span ISO 5/RABS design, smoke studies, contamination prevention, and systemic CAPA, and they generalize far beyond Sato.
DSRV Intelligence
5 min read
May 2026
Your 483 Response Has 15 Business Days. FDA Just Defined the Bar.
FDA's March 2026 draft guidance converts the 483 response from a closeout ritual into a formal test of your investigation quality under 21 CFR 211.192.
DSRV Intelligence
6 min read
May 2026
Your Complaint Investigation Is Closed. FDA Says the Risk Is Not.
FDA's January 2026 warning letter to Cohance Lifesciences rejected a re-opened complaint investigation for the same gap it had the first time. The enforcement record documents what happens when a quality unit treats complaint handling and cleaning validation as separate systems.
DSRV Intelligence
7 min read
May 2026
EU AI Act Delays High-Risk Deadline to December 2027
EU lawmakers reached a provisional deal on May 7 to push the high-risk AI compliance deadline from August 2, 2026 to December 2, 2027. For pharma quality AI programs, the window is larger. The destination has not moved.
DSRV Intelligence
5 min read
Found something in the intelligence that affects your site?
See how Response Strategy can help
The regulatory world doesn't slow down.
Neither should you.
Join QA professionals, regulatory affairs specialists, and stability scientists who rely on DSRV for weekly regulatory updates, quality science deep-dives, and expert commentary.
Free forever. No spam. Unsubscribe any time.
Controlled intake
Before files move, route the question safely.
DSRV starts with a controlled request: the workflow ask, context, urgency, and decision pressure. Confidential files stay out of the public homepage until the intake path confirms the right review lane.
Ask, check the vault, answer or flag the gap, then escalate to Ted/DSRV when regulated judgment matters.
Ask
What decision does the quality team need to make?
Vault
What reviewed evidence, history, or QMS context already answers it?
Gap
What is missing, ambiguous, or unsafe to answer automatically?
Ted/DSRV
What needs human review, training, response strategy, or readiness work?
Coming next: connect your AI to controlled quality intelligence. Not autonomous decisions, not uncontrolled file ingestion, and not a promise of regulatory outcome.